Expert Interview
Discussing TG Therapeutics’ BRIUMVI (ublituximab) in patients with relapsing forms of multiple sclerosis, following Dec 28 FDA Approval
Ticker(s): TGTXA neurologist with experience in treating RMS.
Please describe your clinical practice. How many patients with RMS do you see on a yearly basis? What percent of MS patients relapse, following standard of care medication?
What are the most common causes of relapsing of MS in your patients? Are there specific needs that warrant new therapy choices? Where would you like to see improvements in the treatment of MS?
Added By: slingshot_insightsHow do the available Anti-CD20 mAbs compare to each other? (Rituximab / Ocrelizumab / Ofatumumab). What are the pros and cons of each, and where do you think that Ublituximab could fit in?
Added By: slingshot_insightsWhat’s your impression on the nonglycoengineered vs glycoengineered anti-CD20 antibodies argument that TG Therapeutics is making, claiming that its drug has higher (In vitro) ADCC relative to all other anti-CD20 therapies used in MS?
Added By: slingshot_insightsCan you discuss with us the study design, where 30-60 minutes prior to each dose of ublituximab or IV placebo: antihistamine (diphenhydramine 50 mg or equivalent) and corticosteroid (dexamethasone 10-20 mg or equivalent): oral, IV, IM, and/or SC (investigator discretion). How much could this tilt the balance of results?
Added By: slingshot_insightsCan you please comment on the 13.3%-12.5% Proportion of Patients With IRAP Confirmed Relapse reported in both studies?
How likely are you to prescribe BRIUMVI to your patients, following the FDA Approval? What chances for success do you think it has?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
